In this May 4, 2020 photo provided by the University of Maryland School of Medicine, the first patient enrolled in Pfizer's COVID-19 coronavirus vaccine clinical trial at the University of Maryland Sc
In this May 4, 2020 photo provided by the University of Maryland School of Medicine, the first patient enrolled in Pfizer's COVID-19 coronavirus vaccine clinical trial at the University of Maryland School of Medicine in Baltimore, receives an injection.U.S. drugmaker Pfizer and German biotech BioNTech said they began their late-stage human trial for a potential coronavirus vaccine on Monday as pharmaceutical companies race to win regulatory approval before the end of the year.
The trial will include up to 30,000 participants between the ages of 18 and 85 across 120 sites globally, the companies announced. If successful, they expect to submit it for final regulatory review as early as October. The decision to start the trial reflects "our primary goal to bring a well-tolerated, highly effective vaccine to the market as quickly as possible, while we will continue to evaluate our other vaccine candidates as part of a differentiated COVID-19 vaccine portfolio," BioNTech CEO Ugur Sahin said in a release. "Many steps have been taken towards this important milestone and we would like to thank all those involved for their extraordinary commitment.
The companies' experimental vaccine, uses messenger ribonucleic acid, or mRNA molecules, to provoke an immune response to fight the virus. Scientists hope mRNA, which relays genetic instructions from DNA, can be used to train the immune system to recognize and destroy the virus. Earlier this month, the companies said one of its four coronavirus vaccine candidates produced neutralizing antibodies, which researchers believe is necessary to build immunity to the virus, in all participants who received two of the 10 or 30 microgram doses.
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
Stocks making the biggest moves after hours: Pfizer, F5 Networks, Virgin Galactic and moreSee which stocks are posting big moves after the bell.
続きを読む »
Moderna's COVID-19 vaccine candidate moves into late-stage trialModerna Inc said on Monday it has started a U.S. government-backed late-stage trial for its COVID-19 vaccine candidate, the first to be implemented under the Trump administration's Operation Warp Speed anti-coronavirus program.
続きを読む »
Moderna’s Coronavirus Vaccine Begins Final-Stage TestingModerna’s pivotal vaccine trial will evaluate, in 30,000 subjects across the U.S., whether two doses protects against symptomatic Covid-19
続きを読む »
First Phase 3 clinical trial of a coronavirus vaccine in the United States beginsThe investigational vaccine was developed by the biotechnology company Moderna and the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health. The trial is to be conducted at nearly 100 US research sites, according to Moderna.
続きを読む »
Republican relief plan slashes unemployment benefits by 43% for average workerA coronavirus relief plan unveiled by Senate Republicans on Monday would give $
続きを読む »
Hundreds jam airport as evacuations from Vietnam's Danang beginHundreds flooded the airport in the central Vietnamese tourism hotspot of Danang on Monday after three residents tested positive for the coronavirus and the evacuation of 80,000 people began.
続きを読む »